BURNING ROCK BIOTECH LTD-ADR (BNR)
US12233L1070 - ADR
Taking everything into account, BNR scores 3 out of 10 in our fundamental rating. BNR was compared to 588 industry peers in the Biotechnology industry. The financial health of BNR is average, but there are quite some concerns on its profitability. While showing a medium growth rate, BNR is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year BNR has reported negative net income.
BNR had a negative operating cash flow in the past year.
BNR had negative earnings in each of the past 5 years.
BNR had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of BNR (-62.86%) is worse than 60.45% of its industry peers.
With a Return On Equity value of -85.07%, BNR perfoms like the industry average, outperforming 50.51% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -62.86% | ||
| ROE | -85.07% | ||
| ROIC | N/A |
ROA(3y)-53%
ROA(5y)-43.23%
ROE(3y)-70.7%
ROE(5y)-56.83%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 67.58%, BNR belongs to the best of the industry, outperforming 83.05% of the companies in the same industry.
In the last couple of years the Gross Margin of BNR has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for BNR so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 67.58% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.54%
GM growth 5Y0.89%
2. Health
2.1 Basic Checks
BNR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BNR has been reduced compared to 1 year ago.
BNR has more shares outstanding than it did 5 years ago.
BNR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
BNR has an Altman-Z score of -4.68. This is a bad value and indicates that BNR is not financially healthy and even has some risk of bankruptcy.
BNR has a Altman-Z score of -4.68. This is in the lower half of the industry: BNR underperforms 62.33% of its industry peers.
There is no outstanding debt for BNR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.68 |
ROIC/WACCN/A
WACC7.64%
2.3 Liquidity
A Current Ratio of 3.36 indicates that BNR has no problem at all paying its short term obligations.
BNR has a Current ratio of 3.36. This is in the lower half of the industry: BNR underperforms 62.16% of its industry peers.
A Quick Ratio of 3.09 indicates that BNR has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.09, BNR is doing worse than 64.38% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.36 | ||
| Quick Ratio | 3.09 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 31.65% over the past year.
The Revenue has decreased by -4.55% in the past year.
Measured over the past years, BNR shows a very strong growth in Revenue. The Revenue has been growing by 20.80% on average per year.
EPS 1Y (TTM)31.65%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q24.92%
Revenue 1Y (TTM)-4.55%
Revenue growth 3Y7.73%
Revenue growth 5Y20.8%
Revenue growth Q2Q-14.85%
3.2 Future
Based on estimates for the next years, BNR will show a very negative growth in Earnings Per Share. The EPS will decrease by -29.98% on average per year.
Based on estimates for the next years, BNR will show a quite strong growth in Revenue. The Revenue will grow by 16.93% on average per year.
EPS Next Y55.24%
EPS Next 2Y-29.98%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year20.21%
Revenue Next 2Y33.54%
Revenue Next 3Y18.66%
Revenue Next 5Y16.93%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
BNR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BNR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as BNR's earnings are expected to decrease with -29.98% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-29.98%
EPS Next 3YN/A
5. Dividend
5.1 Amount
BNR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BURNING ROCK BIOTECH LTD-ADR
NASDAQ:BNR (4/26/2024, 7:00:00 PM)
0.85
0 (-0.01%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap87.27M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -62.86% | ||
| ROE | -85.07% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 67.58% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.52
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.36 | ||
| Quick Ratio | 3.09 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)31.65%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y55.24%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-4.55%
Revenue growth 3Y7.73%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y